Ireland's Elan won a $55.2 million judgment against Abraxis BioScience on Friday, prevailing in its case that Abraxis' breast cancer drug Abraxane uses a technology protected by an Elan patent. Abraxane was approved by the FDA three years ago. This fight is far from finished, as Abraxis says it plans to appeal the ruling. - read the report from RTT News ALSO: Investors are anxiously awaiting a Phase II update from Elan and Wyeth on bapineuzumab , a potential blockbuster drug targeted at the root causes of Alzheimer's. Significant success in the clinic would pave the way for a new drug to compete against therapies that offer little long-term benefit. Report Related Articles: AstraZeneca, Abraxis ink $200M licensing pact Abraxis cleaves company into two new outfits ...
Anytime
